Table 1A.
Patient characteristics and type of VTE prophylaxis in all patients undergoing major orthopaedic surgery between January 2005 and December 2009
| Prophylactic LMWH > 3000 aXa once daily mean ± SD | Fondaparinux 2.5 mg once daily mean ± SD | t-test P value | UFH 5000 IU three times daily mean ± SD | Therapeutic LMWH 100–200 aXa kg−1 day−1 mean ± SD | Other pharmacological or mechanical VTE prophylaxis mean ± SD | |
|---|---|---|---|---|---|---|
| n | 1495 | 1994 | 92 | 284 | 31 | |
| Male/Female | 667/828 | 721/1273 | <0.001 (Chi squared) | 47/45 | 149/135 | 12/19 |
| ratio | 0.8 | 0.6 | 1.0 | 1.1 | 0.6 | |
| History of VTE | 0.94% | 0.95% | >0.999 | 3.4% | 24.6% | 6.5% |
| yes/no % (n) | 14/1481 | 19/1975 | 3/89 | 70/214 | 2/31 | |
| Age (years) | 62.3 ± 13.3 | 66. 8 ± 11.9 | <0.001 | 72.1 ± 11.6 | 71.3 ± 9.9 | 67.7 ± 11.5 |
| Height (cm) | 168.5 ± 9.4 | 167.0 ± 9.7 | <0.001 | 167.7 ± 10.6 | 169.1 ± 10.0 | 168.8 ± 6.4 |
| Weight (kg) | 79.4 ± 16.5 | 80.9 ± 18.4 | 0.008 | 80.2 ± 18.3 | 84.4 ± 17.8 | 84.2 ± 14.1 |
| BMI (kg m–2) | 27.9 ± 5.2 | 29.0 ± 5.8 | 0.945 | 28.5 ± 5.9 | 29.4 ± 5.5 | 29.5 ± 5.3 |
| Platelet count (Gpt l–1) | 232.2 ± 83.0 | 207.1 ± 66.6 | <0.001 | 212.2 ± 120.2 | 205.7 ± 76.4 | 250.7 ± 58.0 |
| INR | 1.07 ± 0.12 | 1.11 ± 0.12 | <0.001 | 1.1 ± 0.2 | 1.2 ± 0.4 | 1.1 ± 0.2 |
| aPTT (s) | 28.9 ± 4.5 | 28.6 ± 7.1 | 0.181 | 31.6 ± 8.2 | 30.9 ± 5.1 | 28.4 ± 3.3 |
| Creatinine (µmol l–1) | 64.1 ± 23.1 | 63.1 ± 19.8 | 0.198 | 187.8 ± 146.9 | 72.0 ± 27.2 | 94.1 ± 108.6 |
LMWH = low molecular weight heparin; aXa = anti-Factor Xa units; UFH = unfractionated heparin.